Showing results 1 to 20 of 33
next >
| Preview | Issue Date | Title | Author(s) |
| 2008 | A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer | Rokavec, M.; Schroth, W.; Amaral, S.; Fritz, P.; Antoniadou, L.; Glavac, D.; Simon, W.; Schwab, M.; Eichelbaum, M.; Brauch, H. |
| 2009 | Associations between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with Tamoxifen | Schroth, W.; Goetz, M.; Hamann, U.; Fasching, P.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V.; Ames, M.; Safgren, S.; Kuffel, M.; Ulmer, H.; Bolander, J.; Strick, R.; Beckmann, M.; Koelbl, H.; Weinshilboum, R.; Ingle, J.; Eichelbaum, M.; et al. |
| 2010 | Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression | Hennig, G.; Gehrmann, M.; Stropp, U.; Brauch, H.; Fritz, P.; Eichelbaum, M.; Schwab, M.; Schroth, W. |
| 2008 | Breast cancer risk reduction and membrane-bound catechol o-methyltransferase genetic polymorphisms | Ji, Y.; Olson, J.; Zhang, J.; Hildebrandt, M.; Wang, L.; Ingle, J.; Fredericksen, Z.; Sellers, T.; Miller, W.; Dixon, J.; Brauch, H.; Eichelbaum, M.; Justenhoven, C.; Hamann, U.; Ko, Y.; Bruning, T.; Chang-Claude, J.; Wang-Gohrke, S.; Schaid, D.; Weinshilboum, R. |
| 2007 | Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes | Schroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U.; Simon, W.; Eichelbaum, M.; Brauch, H. |
| 2008 | Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer | Brauch, H.; Schroth, W.; Eichelbaum, M.; Schwab, M.; Harbeck, N. |
| 2010 | CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification | Schroth, W.; Hamann, U.; Fasching, P.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. |
| 2001 | Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique | von Richter, O.; Greiner, B.; Fromm, M.; Fraser, R.; Omari, T.; Barclay, M.; Dent, J.; Somogyi, A.; Eichelbaum, M. |
| 2001 | Distribution of microsomal epoxide hydrolase in humans: An immunohistochemical study in normal tissues, and benign and malignant tumours | Coller, J.; Fritz, P.; Zanger, U.; Siegle, I.; Eichelbaum, M.; Kroemer, H.; Murdter, T. |
| 2010 | Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study | Ribaudo, H.; Liu, H.; Schwab, M.; Schaeffeler, E.; Eichelbaum, M.; Motsinger-Reif, A.; Ritchie, M.; Zanger, U.; Acosta, E.; Morse, G.; Gulick, R.; Robbins, G.; Clifford, D.; Haas, D. |
| 2007 | Effects of rifampicin on global gene expression in human small intestine | Oscarson, M.; Burk, O.; Winter, S.; Schwab, M.; Wolbold, R.; Dippon, J.; Eichelbaum, M.; Meyer, U. |
| 2007 | Functional analysis of the polymorphism - 211C>T in the regulatory region of the human ABCC3 gene | Gradhand, U.; Tegude, H.; Burk, O.; Eichelbaum, M.; Fromm, M.; Konig, J. |
| 2009 | Genetic influences on the pharmacokinetics of orally and intravenously administered Digoxin as exhibited by monozygotic twins | Birkenfeld, A.; Jordan, J.; Hofmann, U.; Busjahn, A.; Franke, G.; Kruger, N.; Igel, S.; Murdter, T.; Drescher, S.; Shi, S.; Engeli, S.; Schwab, M.; Eichelbaum, M.; Luft, F.; Fromm, M. |
| 2008 | Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALDI-TOF mass spectrometry: Reliable genotyping in different ethnic groups | Schaeffeler, E.; Zanger, U.; Eichelbaum, M.; Asante-Poku, S.; Shin, J.; Schwab, M. |
| 2004 | Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans | Glaeser, H.; Drescher, S.; Hofmann, U.; Heinkele, G.; Somogyi, A.; Eichelbaum, M.; Fromm, M. |
| 2007 | Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux | Igel, S.; Drescher, S.; Murdter, T.; Hofmann, U.; Heinkele, G.; Tegude, H.; Glaeser, H.; Brenner, S.; Somogyi, A.; Omari, T.; Schafer, C.; Eichelbaum, M.; Fromm, M. |
| 2004 | Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity | Coller, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T. |
| 2007 | Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4a: Evidence for direct regulation in the intestine | Tegude, H.; Schnabel, A.; Zanger, U.; Klein, K.; Eichelbaum, M.; Burk, O. |
| 2009 | Pharmacogenomics of Tamoxifen Therapy | Brauch, H.; Murdter, T.; Eichelbaum, M.; Schwab, M. |
| 2007 | Predictive value of known and novel alleles ofCYP2B6 for efavirenz plasma concentrations in HIV-infected individuals | Rotger, M.; Tegude, H.; Colombo, S.; Cavassini, M.; Furrer, H.; Decosterd, L.; Blievernicht, J.; Saussele, T.; Gunthard, H.; Schwab, M.; Eichelbaum, M.; Telenti, A.; Zanger, U. |
